2 unknown, 1 not yet recruiting, 1 recruiting, 1 terminated. 4 Phase 2, 2 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Unknown 2, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 2 | Recruiting 1, Unknown 1 |
| Early Phase 1 | 1 | Terminated 1 |
Follow High Risk Acute Lymphoblastic Leukemia: new trials by email Literature Review of High Risk Acute Lymphoblastic Leukemia trials Research Report on High Risk Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT Phase 1 Dose Level 1, Phase 1 Dose Level 2, Phase 1 Dose Level 3 - Leukemia, High Risk Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Children's Hospital of Philadelphia | 100 | 2025-03-21 | 2026-04-15 |
| Blinatumomab Maintenance After Allo-HSCT Blinatumomab - High Risk Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | Ruijin Hospital | 59 | 2024-07-01 | 2024-06-03 |
| CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). Azacitidine Injection, Venetoclax, CD19CD22 CAR-T - B Acute Lymphoblastic Leukemia, Ph-Negative ALL | Phase 2 | Unknown | The First Affiliated Hospital of Soochow University | 20 | 2024-04-20 | 2024-04-22 |
| HCL Single Arm Pilot Study in Treatment of Hyperglycemia of Pediatric ALL Hybrid Closed Loop System - High Risk Acute Lymphoblastic Leukemia | Early Phase 1 | Terminated | University of Colorado, Denver | 1 | 2022-05-12 | 2024-05-03 |
| Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT boost anti-viral immunity after T-cell depleted HSCT - Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 20 | 2021-09-16 | 2021-10-04 |
Lymphoma, Non-Hodgkin (2) · Anemia, Refractory, with Excess of Blasts (1) · Bone Marrow Failure Disorders (1) · Burkitt Lymphoma (1) · Congenital Bone Marrow Failure Syndromes (1) · Hemoglobinopathies (1) · Immunologic Deficiency Syndromes (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Metabolism, Inborn Errors (1) · Myelodysplastic Syndromes (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Virus Diseases (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoma (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Bone Marrow Diseases (2) · Hematologic Diseases (2) · Infections (2) · Anemia (1) · Anemia, Refractory (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · DNA Virus Infections (1)
Azacitidine (1) · Clinical Trials, Phase I as Topic (1) · blinatumomab (1) · venetoclax (1)
Children's Hospital of Philadelphia (1) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · Ruijin Hospital (1) · The First Affiliated Hospital of Soochow University (1) · University of Colorado, Denver (1)
United States (2) · China (1) · Russia (1)
Gregory Forlenza, MD (1) · Timothy Olson, MD, PhD (1)
P30CA046934 (1)